Anakinra serves as an IL-1β receptor antagonist that decreases neuroinflammation, cognitive impairment, and tau phosphorylation, while canakinumab neutralizes IL-1β and prevents its proinflammatory effects (Melchiorri et al. 2023). Here, MAPT is linked to Cognitive impairment.